SVRA

Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara Inc. (SVRA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Profitability (C). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -12.6
EV / EBITDA -7.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -13.6%
Price Return 12M 12.6%
Catalyst Signal 0.00
Market Cap $1.0B
TTM Revenue N/A
Price / Sales N/A
ROE -151.0%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) B (3.4) C (2.3) C+ (2.7) C+ (2.6) C+ (2.7)
2026-11-08 C+ (2.5) B (3.5) C (2.5) C+ (2.6) C+ (2.6) C+ (2.7)
2026-11-01 C+ (2.5) B (3.3) C+ (2.6) C+ (2.8) C+ (2.7) C+ (2.8)
2026-10-25 C+ (2.5) B (3.3) C+ (2.6) C (2.4) C+ (2.6) C+ (2.7)
2026-10-18 C+ (2.5) B (3.3) C+ (2.6) C (2.5) C+ (2.6) C+ (2.7)
Page 1 of 5